Expert Interview
Looking at Sutro Bio’s lead pipeline candidate, STRO-001 CD74-Targeting ADC for Lymphoma & Multiple Myeloma after its recent IPO
Ticker(s): STROAn oncologist or research scientist familiar with Targeting CD74 with Antibody Drug Conjugates.
Please tell us about your professional/clinical experience and background in lymphoma and multiple myeloma.
Added By: c_adminWhat is your preferred first-line of therapy in Lymphoma? In Multiple Myeloma?
Added By: c_adminThe Phase 1 clinical trial of STRO-001 is the first of its kind created using cell-free protein synthesis. Can you please give us your thoughts on this technology and how this approach is unique?
Added By: c_adminIn the first study, the Sutro antibody detected CD74 expression in 35 of the 36 examined bone marrow samples of multiple myeloma patients. In the second study, CD74 was highly-expressed in most samples from patients with diffuse large B-cell lymphoma (135 out of 140, or 96%), follicular lymphoma (148/151, 98%) and mantle cell lymphoma (19/21, 91%). What is your interpretation of this data?
Added By: c_adminIs there something unique to STRO-001 that would facilitate multiple rounds of antibody and ADC optimization, as the company cites?
What would be the pros and cons of STRO-001 in multiple myeloma and non-Hodgkin’s lymphoma, versus therapies already on the market? (cyclophosphamide and vincristine, prednisolone, rituximab, bortezomib, lenalidomide–dexamethasone etc.)
Have you used any of the FDA Approved ADC’s so far (Adcetris for Hodgkin lymphoma and ALCL Besponsa in ALL)? What is your first impression of them, and what would make you switch from what you’re currently using to STRO-001?
Added By: c_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
